Avecho Biotechnology Limited (OEZ) - Net Assets
Based on the latest financial reports, Avecho Biotechnology Limited (OEZ) has net assets worth €3.27 Million EUR (≈ $3.82 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.00 Million ≈ $5.84 Million USD) and total liabilities (€1.73 Million ≈ $2.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OEZ financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.27 Million |
| % of Total Assets | 65.44% |
| Annual Growth Rate | -20.27% |
| 5-Year Change | 23.18% |
| 10-Year Change | -88.7% |
| Growth Volatility | 66.07 |
Avecho Biotechnology Limited - Net Assets Trend (2013–2024)
This chart illustrates how Avecho Biotechnology Limited's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Avecho Biotechnology Limited for the complete picture of this company's asset base.
Annual Net Assets for Avecho Biotechnology Limited (2013–2024)
The table below shows the annual net assets of Avecho Biotechnology Limited from 2013 to 2024. For live valuation and market cap data, see OEZ market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.27 Million ≈ $3.82 Million |
-48.86% |
| 2023-12-31 | €6.39 Million ≈ $7.47 Million |
+163.66% |
| 2022-12-31 | €2.42 Million ≈ $2.83 Million |
-46.55% |
| 2021-12-31 | €4.54 Million ≈ $5.30 Million |
+70.91% |
| 2020-12-31 | €2.65 Million ≈ $3.10 Million |
-44.22% |
| 2019-12-31 | €4.76 Million ≈ $5.56 Million |
+22.03% |
| 2018-12-31 | €3.90 Million ≈ $4.56 Million |
-39.10% |
| 2017-12-31 | €6.40 Million ≈ $7.49 Million |
-45.02% |
| 2016-12-31 | €11.65 Million ≈ $13.62 Million |
-59.74% |
| 2015-12-31 | €28.93 Million ≈ $33.82 Million |
-41.00% |
| 2014-12-31 | €49.03 Million ≈ $57.32 Million |
+24.12% |
| 2013-12-31 | €39.50 Million ≈ $46.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Avecho Biotechnology Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6908375100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €272.66 Million | 8338.94% |
| Total Equity | €3.27 Million | 100.00% |
Avecho Biotechnology Limited Competitors by Market Cap
The table below lists competitors of Avecho Biotechnology Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pursuit Minerals Ltd
AU:PUR
|
$12.51 Million |
|
Zantat Holdings Berhad
KLSE:0301
|
$12.51 Million |
|
Smith Micro Software Inc
NASDAQ:SMSI
|
$12.51 Million |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
$12.51 Million |
|
Magna Terra Minerals Inc
V:MTT
|
$12.51 Million |
|
Energous Corporation
NASDAQ:WATT
|
$12.50 Million |
|
Lion Metal Works Tbk
JK:LION
|
$12.50 Million |
|
Ironman International Ltd.
V:IMI
|
$12.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avecho Biotechnology Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,377,770 to 3,269,738, a change of -3,108,032 (-48.7%).
- Net loss of 3,122,048 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.12 Million | -95.48% |
| Other Changes | €14.02K | +0.43% |
| Total Change | €- | -48.73% |
Book Value vs Market Value Analysis
This analysis compares Avecho Biotechnology Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.82x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.39x to 5.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.00 | €0.01 | x |
| 2018-12-31 | €0.00 | €0.01 | x |
| 2019-12-31 | €0.00 | €0.01 | x |
| 2020-12-31 | €0.00 | €0.01 | x |
| 2021-12-31 | €0.00 | €0.01 | x |
| 2022-12-31 | €0.00 | €0.01 | x |
| 2023-12-31 | €0.00 | €0.01 | x |
| 2024-12-31 | €0.00 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avecho Biotechnology Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -241.29%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.53x
- Recent ROE (-95.48%) is below the historical average (-78.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -31.92% | -1568.03% | 0.02x | 1.06x | €-16.56 Million |
| 2014 | -18.22% | -435.22% | 0.04x | 1.04x | €-13.84 Million |
| 2015 | -69.55% | -918.72% | 0.07x | 1.06x | €-23.01 Million |
| 2016 | -148.66% | -1090.30% | 0.12x | 1.15x | €-18.48 Million |
| 2017 | -133.45% | -742.84% | 0.14x | 1.29x | €-9.19 Million |
| 2018 | -102.34% | -318.69% | 0.26x | 1.23x | €-4.38 Million |
| 2019 | 17.86% | 20.06% | 0.80x | 1.12x | €374.06K |
| 2020 | -99.26% | -685.04% | 0.11x | 1.26x | €-2.90 Million |
| 2021 | -113.60% | -486.43% | 0.20x | 1.16x | €-5.61 Million |
| 2022 | -96.60% | -194.20% | 0.36x | 1.38x | €-2.58 Million |
| 2023 | -53.88% | -725.70% | 0.06x | 1.15x | €-4.07 Million |
| 2024 | -95.48% | -241.29% | 0.26x | 1.53x | €-3.45 Million |
Industry Comparison
This section compares Avecho Biotechnology Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avecho Biotechnology Limited (OEZ) | €3.27 Million | -31.92% | 0.53x | $12.51 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its hum… Read more